Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Nobuyuki Musha"'
Autor:
Tadashi Tanabe, Nobuhiro Morioka, Nobuyuki Musha, Kota Yoshikawa, Hiroshi Ogawa, Akira Kuwahara, Toshihiro Tsubono, Masao Kubota
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 31:21-24
Autor:
Yuki Matsubara, Toshiki Masuishi, Hidekazu Hirano, Saori Mishima, Mitsuhiro Furuta, Tomoyuki Otsuka, Kenta Kawasaki, Takeshi Kawakami, Kazuhiro Yanagihara, Takaya Shimura, Masato Komoda, Kozue Murayama, Keiko Minashi, Yoshiyuki Yamamoto, Yudai Shinohara, Shinichi Nishina, Nobuyuki Musha, Kyoko Kato, Isao Oze, Kei Muro
Publikováno v:
Annals of Oncology. 33:S473
Autor:
Kazuhiro Yoshida, Wataru Ichikawa, Toshio Shikano, Nobuyuki Musha, Masato Kataoka, Masahiro Takeuchi, Hitoshi Ojima, Tsunenobu Takase, Kazushige Shibahara, Sang-Woong Lee, Atsushi Ishiguro, Masashi Fujii, Yoshinori Sakai, Taisei Kimura, Mitsugu Kochi, Yoshihiro Kakeji, Takeshi Sano, Yasuhiro Kodera
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 25(1)
The second planned interim analysis (median follow-up 12.5 months) in a phase III trial of postoperative adjuvant chemotherapy for stage III gastric cancer revealed significant improvement in relapse-free survival (RFS) for S-1 plus docetaxel over S-
Autor:
Hidekazu Hirano, Yuki Matsubara, Toshiki Masuishi, Saori Mishima, Mitsuhiro Furuta, Tomoyuki Otsuka, Kenta Kawasaki, Takeshi Kawakami, Kazuhiro Yanagihara, Takaya Shimura, Masato Komoda, Kozue Murayama, Keiko Minashi, Yoshiyuki Yamamoto, Yudai Shinohara, Shinichi Nishina, Nobuyuki Musha, Kyoko Kato, Isao Oze, Kei Muro
Publikováno v:
Journal of Clinical Oncology. 40:511-511
511 Background: Platinum-based systemic chemotherapy (CTx) is recommended for poorly differentiated advanced gastrointestinal neuroendocrine carcinoma (GI-NEC). As second-line CTx various regimens are adopted according to the guidelines of GI adenoca
Autor:
Yasuo Sakai, Hiroshi Tamura, Nobuyuki Musha, Hidenaka Kokai, Toshihiro Tsubono, Ken Nishikura, Akifumi Kuwabara
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 76:2207-2213
Autor:
K. Nishikawa, Naotoshi Sugimoto, Miki Ito, Ichinosuke Hyodo, Misuzu Mori, Kenichi Yoshimura, Shuichi Hironaka, Keita Uchino, Hirotsugu Yoshiyama, Katsunori Shinozaki, Tsuyoshi Shirakawa, Takeshi Sakamoto, Kazuhiro Nishikawa, Yasutaka Sukawa, Yutaka Kimura, Hiroharu Shinozaki, Shinya Tokunaga, Yoshinori Miyata, Yuji Negoro, Hiroyuki Okuda, Kimio Yonesaka, Toshikazu Moriwaki, Narikazu Boku, Keisei Taku, Nobuyuki Musha, Katsuhiko Nosho, Toshimi Takano, Yuji Miura, Takashi Tsuda
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 21(1)
Five-weekly S-1 plus cisplatin (SP) therapy is the standard care for advanced gastric or esophagogastric junction cancer (GC/EGJC) in East Asia. However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor
Autor:
Toshihiro Tubono, Nobuyuki Musha, Isao Hasegawa, Yasuo Sakai, Yosuke Tajima, Kazuhito Yajima, Tomoki Kido
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 69:509-513
はじめに:鼠径へルニアの治療の原則は手術であるが,妊娠中に発症した鼠径ヘルニアの治療方針は確立していない.対象および方法:1996年から2006年の間に当科で行われた1,032例の鼠径ヘ
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 68:2442-2448
左側大腸穿孔による腹膜炎に対して手術を施行した27症例について, 選択術式別の短期および長期治療成績を検討した. 対象症例を一期的切除・再建を施行した9例 (A群) と人工肛門造設を
Autor:
Kanako Fujita, Kazuyoshi Suda, Nobuyuki Musha, Yukio Takano, Shintaro Komukai, Jun Hasegawa, Ken Saitou
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 67:408-413
Autor:
Katsuyoshi Hatakeyama, Satoshi Yamagiwa, Satoshi Sugahara, Toshiyuki Koya, Yuhei Yoshida, Toru Abo, Hiroshi Watanabe, Nobuyuki Musha
Publikováno v:
Clinical and Experimental Immunology. 113:220-228
SUMMARYA particular T cell population expressing NK cell markers, CD56 and CD57, exists in humans. Many CD56+ T and CD57+ T cells (i.e. NK T cells) exist in the liver and increase in number in the blood with ageing. They may be a human counterpart of